Menzies Institute for Medical Research, University of Tasmania, Private Bag 23, Hobart, 7000, Australia.
Departments of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, Paris, France.
Curr Hypertens Rep. 2017 Jan;19(1):2. doi: 10.1007/s11906-017-0704-7.
The purpose of the review is to examine whether measurement of aortic stiffness could be especially value-adding for risk stratification and treatment among patients with resistant hypertension (RH).
Adverse arterial remodeling and increased aortic stiffness is associated with RH, and it may be of additional clinical benefit to measure aortic stiffness in these patients. However, there is insufficient evidence to determine whether aortic stiffness is excessively high relative to the level of blood pressure (BP) among people with RH. This issue needs resolution as it could help refine management decisions guided by aortic stiffness. If conventional antihypertensive therapy fails to lower BP in patients with RH, there is good rationale for effectiveness of spironolactone as add on therapy, and this should also improve aortic stiffness. Lifestyle intervention with exercise and diet should be additionally efficacious towards improving BP and aortic stiffness in patients with RH, but there is limited data in this patient population. For better characterization on the effects of BP treatment on aortic stiffness, measures of central aortic BP may help refine management decisions above and beyond conventional arm cuff BP. There is strong evidence to support the use of aortic stiffness as a tool to aid risk stratification in hypertension management. Although there is a theoretical basis for special additional benefit of measuring aortic stiffness in patients with RH (as distinct from uncomplicated hypertension), at this time, there is inadequate data available to make definitive conclusions and is an area for future investigation.
本综述旨在探讨测量主动脉僵硬度是否能特别有助于强化治疗抵抗性高血压(RH)患者的危险分层。
动脉重构不良和主动脉僵硬度增加与 RH 相关,测量这些患者的主动脉僵硬度可能具有额外的临床益处。然而,尚没有足够的证据来确定 RH 患者的主动脉僵硬度相对于血压(BP)水平是否过高。这个问题需要解决,因为它可以帮助完善基于主动脉僵硬度的管理决策。如果常规降压治疗不能降低 RH 患者的 BP,螺内酯作为附加治疗的有效性有很好的理由,这也应该改善主动脉僵硬度。对于 RH 患者,运动和饮食的生活方式干预应该对降低血压和主动脉僵硬度更有效,但在这一患者群体中数据有限。为了更好地描述 BP 治疗对主动脉僵硬度的影响,中心动脉 BP 的测量可能有助于完善常规臂袖 BP 之外的管理决策。有强有力的证据支持将主动脉僵硬度作为高血压管理中辅助危险分层的工具。尽管在理论上有理由认为在 RH 患者中测量主动脉僵硬度有特殊的额外益处(与单纯性高血压不同),但目前还没有足够的数据来得出明确的结论,这是未来研究的一个领域。